Precision Medicine Software Market to Reach US$6.61 Billion by 2035 | Precision Medicine Software Market Enters a New Phase as AI Clinical Decision Support Connects Genomic Insights With Treatment

The global precision medicine software market is becoming an increasingly important part of healthcare technology as providers move toward treatment decisions informed by individual genomic, molecular and clinical data. These platforms help healthcare organizations combine information from electronic health records, genetic sequencing, diagnostic testing and clinical research to support patient stratification, disease-risk assessment and treatment selection. Their role is particularly relevant in oncology, where identifying actionable biomarkers and matching patients with targeted therapies can influence clinical decisions.

Request Free Executive Sample: https://www.datamintelligence.com/download-sample/precision-medicine-software-market?sb

According to DataM Intelligence, the global precision medicine software market was valued at US$2.12 billion in 2025 and is projected to reach US$6.61 billion by 2035, registering a CAGR of 12.10% during 2026-2035. North America accounted for the largest regional share, at 48.3% in 2025, supported by established healthcare IT infrastructure, genomic research capabilities and early adoption of digital health platforms. Asia-Pacific is expected to be the fastest-growing region, with a projected CAGR of 14.5%, as healthcare digitization and precision medicine programs expand.

The competitive landscape is shifting from standalone genomic interpretation tools toward connected platforms that support clinical workflows over time. Healthcare providers increasingly need software that can interpret complex molecular results, identify care gaps, track changing treatment guidelines and connect patients with relevant clinical trials. This creates commercial opportunities for software vendors that can demonstrate clinical utility, data interoperability, cybersecurity and integration with existing hospital systems.

Recent Developments in the Precision Medicine Software Market

- October 2026 - Illumina launched its BioInsight Platform, a unified software environment combining genomic analysis applications, AI capabilities and curated biological datasets. The platform is designed to help research organizations interpret complex genomic and multiomic information without assembling multiple disconnected informatics tools. Its DRAGEN v4.6 update also expanded deployment options across supported cloud and standard computing environments, addressing flexibility and data-residency requirements.

- October 2026 - Illumina introduced three early-access capabilities for BioInsight: DRAGEN Ultra, Workflow Orchestrator and Learning Cohorts. These tools are designed to support variant prioritization, automate genomic laboratory workflows and identify patterns across large genomic, multiomic and phenotypic datasets. The additions extend the platform from sequencing analysis toward more integrated research and discovery workflows.

- October 2026 - Oracle Health and Saudi Arabia's King Faisal Specialist Hospital & Research Centre announced a non-binding memorandum of understanding to explore a healthcare collaboration connecting clinical, genomic and research data. The proposed ecosystem would use cloud and AI technologies to support clinical insights and scientific discovery. The initiative illustrates how large healthcare institutions are evaluating integrated data platforms for precision medicine and research applications.

- June 2026 - The U.S. National Institutes of Health released a major expansion of its All of Us Research Program dataset, making information from more than 747,000 participants available to registered researchers. The release included over 535,000 whole-genome sequences linked to nearly 482,000 electronic health records, alongside additional proteomics and RNA sequencing data. The growing dataset provides a broader foundation for genomic analysis, population research and the development of precision medicine applications.

- May 2026 - Foundation Medicine announced plans to introduce advanced digital solutions through integration with Roche's navify Clinical Hub. The planned capabilities include AI-powered clinical trial matching, publication search, patient education materials and digitized guideline mapping for U.S. healthcare providers. The development demonstrates the growing importance of embedding molecular insights and treatment information directly into clinical workflows.

- May 2026 - Tempus AI expanded its Next platform with additional oncology use cases across breast, colorectal, ovarian, prostate and other cancers. The AI-enabled clinical decision support system is designed to identify care gaps by analyzing electronic health record data and highlighting patients who may need guideline-directed biomarker testing. A prospective study across six U.S. community health systems reported improvements in biomarker testing rates following implementation, reinforcing the commercial relevance of workflow-integrated clinical intelligence.

- April 2026 - Tempus launched its automated Active Follow-Up service through its Hub physician portal. The service is designed to notify clinicians when new FDA approvals, treatment options or guideline changes become relevant to patients whose genomic testing has already been completed. This addresses a key limitation of static genomic reports: clinical recommendations can change after the initial test, creating demand for software that keeps patient insights current.

- March 2026 - Japan's Ministry of Health, Labour and Welfare announced the establishment of the Japan Genome Medicine Promotion Organization, which began operations on March 30. The organization is intended to support the return of whole-genome analysis results to patients, promote personalized medicine and develop infrastructure for the use of accumulated genomic data in research and drug discovery. The initiative provides a policy foundation for wider adoption of genomic information systems and related software.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=precision-medicine-software-market&from=report?sb

United States: Recent Industry Developments

✅ In August 2026, PrecisionLife selected Gencove as its U.S. genomics platform partner to launch personalized DNA wellness reports. The partnership combines Gencove's low-pass whole-genome sequencing infrastructure with PrecisionLife's AI-powered genomic analysis and reporting software. The first planned offering focuses on Post-COVID DNA wellness reports, with additional personalized genomic products planned.

✅ In September 2026, Verily Health secured new investment from NVIDIA and additional funding from existing investor CU Healthcare Innovation Fund II to accelerate its precision health AI strategy. The investment supports the expansion of Verily Pre, its data and AI platform designed to help healthcare organizations prepare clinical data for AI applications. The company is also advancing genomic and electronic health record integration through its Forecast 1.0 foundation model.

✅ In September 2026, Helix partnered with Databricks to launch Helix Research Workspaces, a secure research environment for population-scale clinicogenomic analysis. The platform provides approved research partners with access to more than 550,000 linked genomic and clinical records, alongside AI-assisted coding and collaborative analytical tools. The launch aims to accelerate biomarker discovery, patient stratification and precision medicine research.

✅ In September 2026, Memorial Sloan Kettering Cancer Center partnered with OpenEvidence to integrate its OncoKB precision oncology knowledge base into AI-powered clinical workflows. The collaboration combines cancer genomic evidence with patient-specific clinical information to support treatment decision-making. The integration also brings OncoKB into OpenEvidence and connects OpenEvidence with MSK's Epic electronic health record workflow.

Japan: Recent Industry Developments

✅ In August 2026, SB Intuitions, Juntendo University, SoftBank and HEMILLIONS initiated joint research using Med-Sarashina, a Japanese-developed medical-specialized large language model. The collaboration focuses on developing AI-powered diagnostic support and medical documentation tools using clinical datasets, knowledge graphs and advanced model training. The initiative aims to improve clinical reasoning, medical research and the practical adoption of AI across Japanese healthcare institutions.

✅ In October 2026, Paradigm Health partnered with Fujitsu Japan and Japan's National Cancer Center Hospital East to demonstrate AI-powered clinical trial matching using Japanese electronic health records. The study evaluated 3,027 lung cancer patients and demonstrated how its software could identify potential candidates for molecularly targeted clinical trials, including patients requiring additional genetic testing. The collaboration aims to improve patient identification, reduce manual screening workloads and expand precision oncology research in Japan.

Segment Analysis

Cloud-Based Delivery Strengthens Its Market Position

By delivery mode, cloud-based software accounted for 54.5% of the global precision medicine software market in 2025, making it the leading segment. Cloud platforms allow healthcare providers, research institutions and pharmaceutical companies to manage large genomic datasets without maintaining all the required computing infrastructure internally. They also support collaboration between laboratories, hospitals and research networks, while enabling remote access to analytical tools.

Demand is increasingly shaped by the need to integrate genomic sequencing results with clinical records, diagnostic information and research databases. However, healthcare organizations must also address patient-data privacy, cybersecurity, interoperability and data-residency requirements when selecting cloud-based platforms.

Oncology Remains the Primary Application Area

Oncology is the leading application segment because cancer treatment increasingly depends on identifying molecular alterations and matching patients with appropriate targeted therapies. Precision medicine software supports genomic interpretation, biomarker identification, clinical trial matching and treatment decision-making. Pharmacogenomics and rare-disease applications are also gaining importance as genomic testing expands into medication selection, inherited disease diagnosis and research programs.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/precision-medicine-software-market?sb

Regional Market Outlook

United States: Clinical Data Integration and AI Adoption

The United States remains the largest regional market, accounting for 48.3% of global revenue in 2025. Its position is supported by advanced healthcare IT infrastructure, strong biotechnology research activity, genomic testing capabilities and the presence of established precision medicine software providers. The NIH All of Us data expansion also strengthens the research environment by making extensive genomic and electronic health record information available to registered researchers.

Commercial opportunities are developing around software that connects genomic results with treatment guidelines, clinical trial eligibility and longitudinal patient records. Tempus's expansion of its Next platform and Foundation Medicine's planned navify Clinical Hub integration illustrate the direction of competition: vendors are increasingly expected to deliver actionable insights within existing clinical workflows rather than simply provide genomic reports.

Japan: National Genomic Infrastructure Supports Adoption

Japan represents an important growth opportunity within Asia-Pacific, where the precision medicine software market is projected to expand at a 14.5% CAGR. The establishment of the Japan Genome Medicine Promotion Organization provides institutional support for the use of whole-genome analysis, personalized treatment and genomic data in research and drug development.

For software providers, opportunities include genomic data management, clinical interpretation, rare-disease analysis and integration between hospitals, laboratories and research institutions. Companies entering the Japanese market will need to address local data governance, healthcare system requirements and clinical validation expectations. Partnerships with domestic hospitals, academic institutions and diagnostic organizations can help technology providers establish a stronger commercial presence.

Key Companies in the Precision Medicine Software Market

2bPrecise: Develops precision medicine technology designed to integrate genomic information into electronic health records and clinical workflows.
Fabric Genomics: Provides genomic interpretation and clinical decision-support software for rare diseases, inherited conditions and precision medicine applications.
SOPHiA GENETICS: Offers data-driven software and AI-powered analytics to support the interpretation of complex genomic and multimodal healthcare information.
Foundation Medicine: Develops molecular information and digital solutions supporting comprehensive genomic profiling, clinical interpretation and personalized cancer treatment.
Other market participants include PierianDx, Velsera, MediCardia Health and Translational Software.

Market Outlook

The precision medicine software market is expected to benefit from the increasing integration of genomic testing, electronic health records, AI analytics and clinical decision-support systems. Cloud-based platforms are likely to remain important as healthcare organizations seek scalable infrastructure for managing complex datasets and collaborating across institutions. Oncology will continue to provide a major commercial application, while pharmacogenomics and rare-disease analysis offer additional opportunities for specialized software providers.

Future competition will depend on clinical relevance, analytical accuracy, interoperability and the ability to incorporate new scientific evidence into existing workflows. Vendors that can connect molecular findings with treatment guidelines, clinical trial opportunities and longitudinal patient information will be better positioned to address healthcare providers' needs. At the same time, regulatory compliance, data security and implementation costs will remain important considerations for adoption across both established and emerging healthcare markets.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.